Key result
Integrilin during PTCA and stenting is linked to 0% severe bleeding or thrombotic complications.
Observational (n=21)
Answers are grounded in this paper and cite their sources.
May support early sheath removal with Integrilin post-stenting; leaves open confirmation in larger randomized trials.
Objective: to report the application of GPIIb/IIIa antagonist (Integrilin) in peri-percutaneous transluminal catheter angioplasty and stent implantation in Chinese. Method: Twenty-one patients who underwent percutaneous transluminal catheter angioplasty (PTCA) and stent implantation were included. After arterial puncture, integrilin was injected at dose of 180μg/kg, and then maintained at 2/μg/kg·min for 18 hours. Asprine, plavix(clopidogrel) and heparin were used at the same time. ACT, PT, KPTT and blood routine were routinely monitored. Results: All sheaths were drawn out 2 to 4 hours after the procedure., There was no severe complication such as hematoma, acute and subacute thrombosis in coronary artery, or thrombocytopenia. ACT returned to less than 150 seconds in 2 hours in 15 patients; in 4 hours in 6 patients. There was no significant difference between the pre- and post-procedure value of PT and platelet count. KPTT was significantly higher than pre-procedure value at 2 hours after the procedure. No recurrence of angina pectoris was observed in the first nine patients within one year follow-up, and no restenosis occurred in stents in the five patients who had coronary angiography one year later. Conclusion: Application of GPIIb/IIIa receptor antagonist (Integrilin) in peri-percutaneous transluminal catheter angioplasty and stent implantation in combination with aspirin and plavix could significantly reduce the dosage and duration of heparin with benefit of shortening the indwelling time of sheaths, but did not increase risk of bleeding or lead to thrombosis in stent.
No takes yet. Share an insight, caveat, or question.
Yong Sun (2002) conducted an observational in Patients undergoing percutaneous transluminal catheter angioplasty (PTCA) and stent implantation (n=21). Glycoprotein IIb/IIIa antagonist (Integrilin) with aspirin, clopidogrel, and heparin was evaluated on Severe complications (hematoma, acute and subacute thrombosis in coronary artery, or thrombocytopenia). Integrilin administration during PTCA and stent implantation resulted in 0% severe bleeding or thrombotic complications among 21 patients, allowing sheath removal in 2 to 4 hours.
Synapse has enriched 10 related papers. Consider them for comparative context: